BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16010649)

  • 1. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
    Vamvakas EC
    Transfus Med Rev; 2005 Jul; 19(3):181-99. PubMed ID: 16010649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of transfusion-transmitted cytomegalovirus infection.
    Pamphilon DH; Rider JR; Barbara JA; Williamson LM
    Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
    Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.
    Preiksaitis JK; Sandhu J; Strautman M
    Transfusion; 2002 Apr; 42(4):396-402. PubMed ID: 12076284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
    Hall S; Danby R; Osman H; Peniket A; Rocha V; Craddock C; Murphy M; Chaganti S
    Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study.
    Preiksaitis JK; Desai S; Vaudry W; Roberts S; Akabutu J; Grundy P; Wilson B; Boshkov L; Hannon J; Joffres M
    Transfusion; 1997 Sep; 37(9):941-6. PubMed ID: 9308642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leukocyte depletion and infection by cytomegalovirus].
    Mazeron MC
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():31s-35s. PubMed ID: 10919221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
    Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.
    Ziemann M; Krueger S; Maier AB; Unmack A; Goerg S; Hennig H
    Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.
    Mainou M; Alahdab F; Tobian AA; Asi N; Mohammed K; Murad MH; Grossman BJ
    Transfusion; 2016 Jun; 56(6 Pt 2):1569-80. PubMed ID: 26826015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.
    Morton S; Peniket A; Malladi R; Murphy MF
    Transfus Med; 2017 Dec; 27(6):444-450. PubMed ID: 28913908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
    Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
    Nichols WG; Price TH; Gooley T; Corey L; Boeckh M
    Blood; 2003 May; 101(10):4195-200. PubMed ID: 12531791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion-associated cytomegalovirus infections.
    Adler SP
    Rev Infect Dis; 1983; 5(6):977-93. PubMed ID: 6318291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.